Impurities in Oligonucleotide Drug Substances and Drug Products

被引：78

作者：

Capaldi, Daniel ^{[1
]}

Teasdale, Andy ^{[2
]}

Henry, Scott ^{[1
]}

Akhtar, Nadim ^{[2
]}

den Besten, Cathaline ^{[3
]}

Gao-Sheridan, Samantha ^{[4
]}

Kretschmer, Matthias ^{[4
]}

Sharpe, Neal ^{[5
]}

Andrews, Ben ^{[6
]}

Burm, Brigitte ^{[7
]}

Foy, Jeffrey ^{[8
]}

机构：

[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA

[2] AstraZeneca UK Ltd, Macclesfield, Cheshire, England

[3] ProQR Therapeut NV, Leiden, Netherlands

[4] Alnylam Pharmaceut Inc, Cambridge, MA USA

[5] Anavex Life Sci Corp, New York, NY USA

[6] GlaxoSmithKline, Stevenage, Herts, England

[7] ISA Therapeut, Leiden, Netherlands

[8] Celgene Corp, Summit, NJ USA

来源：

NUCLEIC ACID THERAPEUTICS | 2017年 / 27卷 / 06期

关键词：

oligonucleotides; impurities; identification; qualification; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY GEL-ELECTROPHORESIS; IONIZATION MASS-SPECTROMETRY; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; INTERFERING RNA; NUCLEIC-ACIDS; THERAPEUTICS; DNA; RECOMMENDATIONS; OLIGODEOXYNUCLEOTIDES;

D O I：

10.1089/nat.2017.0691

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider chemistry and safety aspects and advance arguments in favor of platform approaches to impurity identification and qualification. Reporting, identification, and qualification thresholds suitable for product-related impurities of therapeutic oligonucleotides are proposed.

引用

页码：309 / 322

页数：14

共 50 条

[1] COMPREHENSIVE APPROACH OF QBD FOR IMPURITIES IN DRUG SUBSTANCES AND DRUG PRODUCTS
Anand, Savkare D.
Nanda, Badhe R.
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 3 (02): : 81 - 85
[2] Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products
Capaldi, Daniel
Akhtar, Nadim
Atherton, Tom
Benstead, David
Charaf, Ayman
De Vijlder, Thomas
Heatherington, Carl
Hoernschemeyer, Joerg
Jiang, Hong
Rieder, Ulrike
Ring, Francis
Peter, Robert
Stolee, Jessica A.
Wechselberger, Rainer
NUCLEIC ACID THERAPEUTICS, 2020, 30 (05) : 249 - 264
[3] Impurities in drug substances and drug products: New approaches to quantification and qualification
Berridge, JC
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 14 (1-2) : 7 - 12
[4] LC Determination of Diastereomeric Impurities of Entecavir in Drug Substances and Drug Products
Balaji, N.
Sultana, Sayeeda
RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2016, 7 (04): : 1848 - 1859
[5] Regulation of genotoxic and carcinogenic impurities in drug substances and products
McGovern, Timothy
Jacobson-Kram, David
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2006, 25 (08) : 790 - 795
[6] 'Quality by Design' approach for the analysis of impurities in pharmaceutical drug products and drug substances
Dispas, Amandine
Avohou, Hermane T.
Lebrun, Pierre
Hubert, Philippe
Hubert, Cedric
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2018, 101 : 24 - 33
[7] Low Level Impurities in Drug Substances and Drug Products and the Analytical Challenges in Identification and Quantitation
Mohan, Ganapathy
PHARMACEUTICAL STABILITY TESTING TO SUPPORT GLOBAL MARKETS, 2010, 12 : 117 - 121
[8] Strategies To Address Mutagenic Impurities Derived from Degradation in Drug Substances and Drug Products
Kleinman, Mark H.
Elder, David
Teasdale, Andrew
Mowery, Mark D.
McKeown, Alan P.
Baertschi, Steven W.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) : 1447 - 1457
[9] Genotoxic Impurities in Drug Substances
Snodin, David
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (03) : 409 - 409
[10] Impurities Testing of Drug Products
Haigney, Susan
Pharmaceutical Technology, 2023, 47 (06) : 32 - 33

← 1 2 3 4 5 →